Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Algeta
December 19, 2016
Interview – Nordic Nanovector exits a glowing year
December 09, 2016
Snippet roundup: Ash cash rolls in, Voyager boldly goes, but Northwest heads south
January 20, 2016
Asco-GI preview – Lutathera delivers again
March 04, 2015
Bristol bets that yesterday’s prostate vaccine could score tomorrow
February 28, 2014
Bankers pitching biotech acquisitions to Bayer must fight hard
January 29, 2014
As Xtandi Prevails, Medivation stays ahead of the curve
November 26, 2013
At long last Bayer makes offer for Algeta
October 10, 2013
Bayer shows big pharma that a conglomerate can do it too
September 13, 2013
Yervoy’s prostate cancer flop points the way to another combo
August 12, 2013
Dendreon’s hero to goat story reaches crisis stage
June 06, 2013
Asco Event Analyzer – 2013’s winners and losers
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 17, 2023
JP Morgan Healthcare Conference 2023
January 12, 2023
Evaluate Vantage 2023 Preview Infographic
Editor's Picks
January 03, 2023
The biggest-selling pharma companies of 2023
January 05, 2023
The biggest-selling drugs of 2023
January 05, 2023
Flotations fail to bounce back
January 06, 2023
Fate runs out of excuses
December 15, 2022
Ash 2022 roundup
